Cargando…
Shuganjieyu capsule increases neurotrophic factor expression in a rat model of depression
Shuganjieyu capsule has been approved for clinical treatment by the State Food and Drug Ad-ministration of China since 2008. In the clinic, Shuganjieyu capsule is often used to treat mild to moderate depression. In the rat model of depression established in this study, Shuganjieyu capsule was admini...
Autores principales: | Fu, Jinhua, Zhang, Yingjin, Wu, Renrong, Zheng, Yingjun, Zhang, Xianghui, Yang, Mei, Zhao, Jingping, Liu, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153504/ https://www.ncbi.nlm.nih.gov/pubmed/25206843 http://dx.doi.org/10.4103/1673-5374.130067 |
Ejemplares similares
-
Compound Shuganjieyu Capsule on CYP450 Enzyme Activity
por: Tang, Yunqiu, et al.
Publicado: (2022) -
Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis
por: Wang, Lingning, et al.
Publicado: (2022) -
Minocycline and Risperidone Prevent Microglia Activation and Rescue Behavioral Deficits Induced by Neonatal Intrahippocampal Injection of Lipopolysaccharide in Rats
por: Zhu, Furong, et al.
Publicado: (2014) -
Efficacy and safety of the Chinese herbal medicine shuganjieyu with
and without adjunctive repetitive transcranial magnetic stimulation (rTMS) for
geriatric depression: a randomized controlled trial
por: XIE, Minmin, et al.
Publicado: (2015) -
The Anti-Depression-Like Effects of Zhengtian Capsule via Induction of Neurogenesis and the Neurotrophic Signaling Pathway
por: Yang, Liang, et al.
Publicado: (2020)